Notice

The database server is currently not answering requests properly. Some pages are still available due to caching. We are investigating the situation and will keep you updated.

A drug discovery platform to identify compounds that inhibit EGFR triple mutants

Journal: Nature Chemical Biology

Published: 2020-02-24

DOI: 10.1038/s41589-020-0484-2

Affiliations: 23

Authors: 38

Go to article
Institutions Share
Terrence Donnelly Centre for Cellular and Biomolecular Research (CCBR), U of T, Canada 0.27
Drug Discovery Program, OICR, Canada 0.18
Princess Margaret Cancer Centre, U of T, Canada 0.14
University Hospital Centre Zagreb (KBC Zagreb), Croatia 0.05
Division of Cell Biology, Neurobiology and Biophysics, UU, Netherlands 0.05
Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Germany 0.05
Department of Molecular Genetics, U of T, Canada 0.05
Lunenfeld-Tanenbaum Research Institute (LTRI), U of T, Canada 0.04
SPARC BioCentre, SickKids U of T, Canada 0.03
Department of Pharmacology and Toxicology, U of T, Canada 0.01
Department of Medicine, U of T, Canada 0.01
Division of Medical Oncology and Hematology, U of T, Canada 0.01
Department of Agricultural, Food and Environmental Sciences, University of Perugia, Italy 0.01
Leslie Dan Faculty of Pharmacy, U of T, Canada 0.01
Peter Gilgan Centre for Research and Learning, SickKids U of T, Canada 0.01
Yale Cancer Biology Institute (YCBI), United States of America (USA) 0.01
Yale Department of Pharmacology, United States of America (USA) 0.01
Department of Medical Biophysics, U of T, Canada 0.01
Department of Laboratory Medicine and Pathobiology (LMP), U of T, Canada 0.01
Department of Biochemistry, U of T, Canada 0.01
Mediterranean Institute for Life Sciences, Croatia 0.01

Return